Chiome Bioscience Inc. Logo

Chiome Bioscience Inc.

Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.

4583 | T

Overview

Corporate Details

ISIN(s):
JP3205350006
LEI:
Country:
Japan
Address:
渋谷区本町三丁目12番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chiome Bioscience Inc. is a clinical-stage biotechnology company established in 2005, specializing in the research and development of therapeutic antibodies. The company focuses on addressing unmet medical needs by creating innovative antibody-based drugs. It utilizes a portfolio of proprietary technologies, most notably its ADLib® system, to accelerate the discovery and selection of optimal antibody candidates for its drug pipeline. Chiome Bioscience is engaged in advancing its own therapeutic programs and providing antibody development support and services to partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-12 09:05
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-08-12 09:04
Interim Report
半期報告書-第22期(2025/01/01-2025/12/31)
Japanese 188.7 KB
2025-03-28 08:09
Governance Information
内部統制報告書-第21期(2024/01/01-2024/12/31)
Japanese 22.8 KB
2025-03-28 08:07
Registration Form
確認書
Japanese 8.3 KB
2025-03-28 08:05
Annual Report
有価証券報告書-第21期(2024/01/01-2024/12/31)
Japanese 1.6 MB
2025-03-28 08:03
Post-Annual General Meeting Information
臨時報告書
Japanese 30.6 KB
2025-02-19 08:04
Audit Report / Information
臨時報告書
Japanese 19.7 KB
2024-11-15 07:48
Registration Form
確認書
Japanese 8.4 KB
2024-11-15 07:45
Annual Report
訂正有価証券報告書-第20期(2023/01/01-2023/12/31)
Japanese 767.5 KB
2024-08-13 09:10
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-08-13 09:08
Interim Report
半期報告書-第21期(2024/01/01-2024/12/31)
Japanese 226.8 KB
2024-07-05 08:02
Registration Form
有価証券届出書(組込方式)
Japanese 264.6 KB
2024-05-14 09:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/01/01-2024/03/31)
Japanese 185.2 KB
2024-05-14 09:12
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-03-26 08:50
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB

Automate Your Workflow. Get a real-time feed of all Chiome Bioscience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chiome Bioscience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chiome Bioscience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.